^
Association details:
| Biomarker: | CBL mutation |
|---|---|
| Cancer: | Chronic Myelomonocytic Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1
Published date:
01/07/2021
Excerpt:
…we demonstrated in vitro and in vivo antiproliferative efficacy of dasatinib in CBL-mutant cell lines and primary CMML.
DOI:
10.1182/blood.2020006528
